NCT06392230View on ClinicalTrials.gov

A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body.

PHASE1CompletedINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

August 30, 2024

Primary Completion Date

November 11, 2024

Study Completion Date

November 11, 2024

Conditions
Healthy Participants
Interventions
DRUG

Oral [14C] PF-06821497

A single oral dose of \[14C\] PF-06821497 will be administered as an extemporaneous suspension in Period 1

DRUG

Oral PF-06821497

A single oral dose of PF-06821497 will be administered as an extemporaneous oral suspension in Period 2

DRUG

IV [14C] PF-06821497

A single IV infusion of \[14C\] PF-06821497 will be administered at the Tmax after administration of the unlabeled oral dose of PF-06821497 in Period 2

Trial Locations (1)

9728 NZ

PRA Health Sciences, Groningen

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT06392230 - A Study to Learn How the Medicine Called [14C] PF-06821497 is Taken up Into and Removed From the Body. | Biotech Hunter | Biotech Hunter